Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT02869490
Recruiting Observational

Institut Paoli Calmettes Cervical Cancer Database

NCT02869490 · tracked via the Priya Life Science France tracker
Sponsor
Institut Paoli-Calmettes
Phase
Observational
Started
2002-01
Last updated
2016-08-17

Condition(s) studied

Uterine Cervical Neoplasms

Investigational drug(s) / intervention(s)

Data collection

Study summary

Database of Institut Paoli-Calmettes patients diagnosed with cervical cancer

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
95 Years
Healthy volunteers
No
Inclusion Criteria: * Patient with a diagnosis of cervical cancer Exclusion Criteria: * Non applicable

Primary outcome measure(s)

  • Survival of patients with cervical cancer — 10 years
    Overall survival of all patients who come in the center

Trial sites (1)

FacilityCityRegionStatus
Institut Paoli Calmettes Marseille Bouches du Rhone Recruiting

More Institut Paoli-Calmettes trials in France

Institut Paoli Calmettes Hepatic Surgery Database Recruiting
Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers Starting soon
Evaluation of the Efficacy of Duodenal Prostheses Not Covered Over 6 Years Recruiting
Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy Recruiting

Other trials for the same condition

Post-TRaUmatic STress Disorder Induced by Gynecological Brachytherapy Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors Recruiting
A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02869490 on ClinicalTrials.gov ↗ ← All trials in France